| ¿µ¹® | prostate gland | ÇÑ±Û | Àü¸³»ù |
|---|---|---|---|
| ¼³¸í | ³²¼º»ý½Ä±âÀÇ ¿ÜºÐºñ»ùÀÇ ÀÏÁ¾À¸·Î, ¹æ±¤ÀÇ ¸ñºÎºÐ°ú ¿äµµ¸¦ µÑ·¯½Î°í ÀÖ´Ù. Àü¸³»ùÀº Á¤¾×À» ¸¸µå´Â Àü¸³»ù¾×À» ºÐºñÇϸç 5°³ÀÇ ¿±À¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. |
||
| ¿µ¹® | neonatal intensive care center | ÇÑ±Û | ½Å»ý¾Æ ÁýÁßÄ¡·á½Ç |
|---|---|---|---|
| ¼³¸í | ¹Ì¼÷¾Æ³ª °¡»ç »óÅÂÀÇ Ãâ»ê¾Æ¸¦ ÁýÁßÀûÀ¸·Î º¸»ìÇǰí Ä¡·áÇÏ´Â ±â°ü. |
||
| ¿µ¹® | intensive care unit | ÇÑ±Û | ÁßȯÀÚ½Ç |
|---|---|---|---|
| ¼³¸í | º´¼¼³ª »óó µûÀ§ÀÇ Á¤µµ°¡ ¸Å¿ì ½ÉÇÑ »ç¶÷À» Ä¡·áÇÏ°í µ¹º¼ ¼ö ÀÖµµ·Ï ¸¶·ÃÇÑ ¹æ. È£Èí-¼øÈ¯-´ë»ç µî Á¤½ÅÀû ±Þ¼º±â´É»ó½ÇÀÇ È¯ÀÚ¸¦ Ãë±ÞÇÏ¸ç °·ÂÇÏ°íµµ ÁýÁßÀûÀÎ Áø·á¸¦ ÇÏ´Â ºÎºÐÀÌ´Ù. À§µ¶ÇÑ È¯ÀÚ¿¡ ´ëÇÏ¿©´Â 24½Ã°£ üÁ¦·Î ´ëÀÀÇÑ´Ù. ÃæºÐÈ÷ ÈÆ·ÃÀ» ¹ÞÀº ÀÇ·áÁøÀÌ ¹èÄ¡µÇ¸ç ±â´ÉÀûÀ¸·Î ¼³ºñ°¡ °®Ãß¾îÁ® ÀÖ´Ù. ½É±Ù°æ»öÁõ-È£Èí±â´É»ó½Ç-ÄáÆÏ±â´É»ó½Ç-¼Ò¾Æ-½Å°æ¿Ü°ú°è µî ƯÁ¤È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ´Ù. |
||
| ¿µ¹® | oral administration | ÇÑ±Û | °æ±¸º¹¿ë |
|---|---|---|---|
| ¼³¸í | ¾àÀ» Åõ¿©ÇÏ´Â ¹æ¹ý¿¡´Â ¿©·¯ °¡Áö°¡ ÀÖ´Ù. Å©°Ô ³ª´©¾î º¸¸é, ÀÔÀ» °ÅÃÄ À§Ã¢Àڰ踦 ÅëÇØ ³Ö´Â ¹æ¹ý°ú À§Ã¢Àڰ踦 ÅëÇÏÁö ¾Ê°í ¹Ù·Î Ç÷¾×À¸·Î ³Ö´Â ¹æ¹ýÀÌ ÀÖ´Ù. À§Ã¢Àڰ踦 ÅëÇÏÁö ¾Ê´Â ¹æ¹ýÀ¸·Î °¡Àå ÈçÇÑ ¹æ¹ýÀº Áֻ縦 ÀÌ¿ëÇÏ´Â ¹æ¹ýÀÌ´Ù. ÇÏÁö¸¸, À̿ܿ¡ Ç×¹®À» ÅëÇØ ³Ö´Â Á¾à½Ä¹æ¹ý°ú Çô¹Ø¿¡ ³Ö´Â Çô¹ØÅõ¿©¹ýµµ ÀÖ´Ù. ±×·¯³ª ´ëºÎºÐÀÇ ¾àÁ¦´Â °æ±¸º¹¿ëÀ» ÇÏ°Ô µÈ´Ù. °æ±¸º¹¿ë¿¡ ´ëÇÑ ¾àÀÚ´Â p.o.(per oral)·Î Ç¥±âÇÑ´Ù. °æ±¸º¹¿ëÁ¦ÀÇ ´ÜÁ¡Àº º¹¿ëÇÑ ¾àÁ¦°¡ À§Ã¢ÀÚ°ü°è¸¦ °ÅÄ¡¸é¼ »ç¶÷¸¶´Ù °¢±â ´Ù¸¥ Èí¼öÁ¤µµ¿Í ´ë»çÁ¤µµ¸¦ °ÅÄ¡°Ô µÇ¹Ç·Î ÀÏÁ¤ÇÑ ³óµµÀ¯Áö°¡ ¾î·Æ´Ù´Âµ¥ ÀÖ´Ù. ¶ÇÇÑ °æ±¸º¹¿ëÁ¦ÀÇ ¸ð¾çÀÌ Ä¸½¶ÇüÀÎÁö, ȤÀº °¡·çÇüÀÎÁö¿¡ µû¶ó¼µµ °°Àº ¾àÀÌÁö¸¸, ¼·Î ´Ù¸¥ È¿°ú¸¦ ³ªÅ¸³¾ ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | oral cavity | ÇÑ±Û | ±¸° |
|---|---|---|---|
| ¼³¸í | ÀÔÀ» ¹ú¿©¼ ÀÔ¼Ó¿¡¼ º¼ ¼ö ÀÖ´Â °ø°£À¸·Î ÀÔõÀå, Æíµµ, ¸ñÁ¥À» º¼ ¼ö ÀÖ´Ù. ![]() |
||
| TSB | total serum bilirubin; trypticase soy broth; tryptone soy broth |
|---|---|
| ORS | olfactory reference syndrome; oral rehydration solution; oral surgery, oral surgeon; Orthopaedic Res... |
| CCC | care-cure coordination; cathodal closure contraction; chronic calculous cholecystitis; chronic catar... |
| PCA | para-chloramphetamine; parietal cell antibody; passive cutaneous anaphylaxis; patient care assistant... |
| PCC | Pasteur Culture Collection; percutaneous cecostomy; pheochromocytoma; phosphate carrier compound; pl... |
| SBA | Soy Bean Agglutinin |
|---|---|
| SBTI | Soy bean trypsin inhibitor |
| SPI | Soy protein isolate |
| TSA | Trypitic Soy Agar |
| TSB | Tryptic Soy Broth |
| soy | 1. A Chinese and Japanese liquid sauce for fish, etc, made by subjecting boiled beans (especially. Soja beans), or beans and meal, to long fermentation and then long digestion in salt and water. 2. <botany> The soja, a kind of bean. See Soja. Origin: Chinese shoyu. Source: Websters Dictionary (01 Mar 1998) |
|---|---|
| soy proteins | Proteins which are present in or isolated from soybeans. (12 Dec 1998) |
| amyloid bodies of the prostate | An obsolete term for small masses of colloid material often present in the tubules of the gland. See: corpus amylaceum. (05 Mar 2000) |
| anterior surface of prostate | The anterior surface of the prostate. Synonym: facies anterior prostatae. (05 Mar 2000) |
| apex of prostate | The lowermost part of the prostate, situated above the urogenital diaphragm. Synonym: apex prostatae. (05 Mar 2000) |
| base of prostate | The broad upper surface of the prostate contiguous with the bladder wall. Synonym: basis prostatae. (05 Mar 2000) |
| cancer, prostate | Cancer of the gland that produces some of the components of semen fluid. Prostate cancer is the second leading cause of death of males in the U.S. Prostate cancer is often first detected as a hard nodule during a routine rectal examination. The PSA blood test is a screening test for prostate cancer. Diagnosis of prostate cancer is established when cancer cells are identified in prostate tissue obtained by a biopsy. In some patients, prostate cancer is life threatening. In many others, prostate cancer can exist for years without causing any health problems. Treatment options for prostate cancer include observation, radiation therapy, surgery, hormonal therapy, and chemotherapy. (12 Dec 1998) |
| glandular substance of prostate | The glandular tissue of the prostate as distinct from the stroma and capsule. Synonym: substantia glandularis prostatae. (05 Mar 2000) |
| middle lobe of prostate | The portion of the prostate lying between the urethra and the ejaculatory ducts; indistinct unless hypertrophied. Synonym: lobus medius prostatae, Morgagni's caruncle. (05 Mar 2000) |
| muscular substance of prostate | The smooth muscle in the stroma of the prostate. Synonym: substantia muscularis prostatae, musculus prostaticus. (05 Mar 2000) |
| posterior surface of prostate | The posterior surface of the prostate. Synonym: facies posterior prostatae. (05 Mar 2000) |
| prostate | A small conical gland at the base of the male bladder and surrounding the first part of the urethra. (27 Sep 1997) |
| prostate acid phosphatase | An enzyme produced by the prostate that is elevated in some patients with prostate cancer. (12 Dec 1998) |
| prostate anatomy | <radiology> Periurethral glandular tissue, may lead to BPH, prostatic acinar tissue, central zone may lead to BPH, peripheral zone may lead to carcinoma (12 Dec 1998) |
| prostate cancer | The second most common malignancy in men. A malignant tumour of glandular origin in the prostate. Over 95% are adenocarcinomas. Most commonly seen in older men, with the age of 73 being the average age at the time of diagnosis. A family history for prostate cancer and perhaps, a diet that is high is fat are considered to be risk factors for this malignancy. Early detection is possible through annual digital rectal examinations and routine PSA testing. (27 Sep 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|